|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.52 | 88.89 | 103.80 | 0.54 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
6505.50
|
|
|
52-Week-Low (Rs.)
|
4383.40
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
( Rs. in Million)
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Profit Before Tax | 38,660.00 | 22,238.00 | 30,562.00 | 27,758.00 | 17,007.00 | Adjustment | 10,458.00 | 8,451.00 | 2,733.00 | 6,818.00 | 9,581.00 | Changes In working Capital | 9,237.00 | -12,414.00 | 6,327.00 | -11,415.00 | 3,421.00 | Cash Flow after changes in Working Capital | 58,355.00 | 18,275.00 | 39,622.00 | 23,161.00 | 30,009.00 | Cash Flow from Operating Activities | 50,528.00 | 13,387.00 | 35,142.00 | 18,392.00 | 27,621.00 | Cash Flow from Investing Activities | -34,476.00 | -20,380.00 | -14,580.00 | -16,892.00 | -5,509.00 | Cash Flow from Financing Activities | -26,969.00 | 5,055.00 | -7,943.00 | -2,241.00 | -22,231.00 | Net Cash Inflow / Outflow | -10,917.00 | -1,938.00 | 12,619.00 | -741.00 | -119.00 | Opening Cash & Cash Equivalents | 11,595.00 | 13,054.00 | 391.00 | 1,132.00 | 1,207.00 | Cash & Cash Equivalent on Amalgamation / Take over / Merger | 0 | 0 | 0 | 0 | 0 | Cash & Cash Equivalent of Subsidiaries under liquidations | 0 | 0 | 0 | 0 | 0 | Translation adjustment on reserves / op cash balalces frgn subsidiaries | 0 | 0 | 0 | 0 | 0 | Effect of Foreign Exchange Fluctuations | 445.00 | 479.00 | 44.00 | 0 | 44.00 | Closing Cash & Cash Equivalent | 1,123.00 | 11,595.00 | 13,054.00 | 391.00 | 1,132.00 |
|
|
|
|
|
|